Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

The Gmail mobile apps lack a handful of features found on the website, but Google is now adding the ability to create new labels on Android. Once available, open the navigation drawer for “Create ...

After testing the feature since December, Google is finally rolling out “create and manage labels” to Gmail for Android. Previously exclusive to desktop and iOS, this update allows Android users to ...

Gmail for Android is finally catching up to the iOS version with the addition of a useful feature. You can now create new labels directly on the Android app. The Android app still doesn’t allow ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

Amgen Inc (NASDAQ: AMGN) reported better-than-expected fourth-quarter revenues and earnings, while witnessing "strength across key drivers (Repatha, Uplizna), even before the full impact of recent ...